This cross-over study investigated the efficacy of highly aspherical lenslet (HAL) lenses to slow myopic progression for Vietnamese children. Switching from single vision to HAL lenses gave a slowing of myopia progression demonstrated by lesser axial elongation. Switching from HAL to SV did not demonstrate a myopia rebound effect.
This 1-yr extension of a previous 2-yr clinical trial investigated myopia control efficacy of highly aspherical lenslet (HAL) spectacle lenses for children wearing them for a further year and for children switching to HAL after wearing slightly aspherical lenslet (SAL) or single vision lenses. HAL design lenses were able to provide or maintain a myopia slowing effect for all wearers.
The LAMP2 study explored the efficacy of low-concentration atropine to delay the onset of myopia in at-risk children. The results found there was no significant difference between 0.01% atropine and the placebo, but 0.05% atropine was able to reduce myopia incidence and speed of myopic progression for pre-myopes.
A mixed-race cohort of Australian children demonstrated that atropine 0.01% was safe and well tolerated, although myopia control effects were only found in those of European or other/mixed ancestry. Those of East Asian or South Asian ethnicity showed no benefit. Overall results were impacted by high drop-out in the control group in the second year of the study.
Low dose atropine is a popular off-label choice for myopia control, and typically needs to be compounded. The results of this survey show there are varying methods for producing, storing and labelling low concentration, compounded atropine in the Unites States. This could influence the safety and efficacy of these atropine formulations for myopia control.
This study created percentile charts for axial length and axial length to corneal radius of curvature (AL/CR) ratio for Chinese children and found age and gender-specific differences in the data. The AL/CR ratio was found to be a more accurate predictor of myopia than axial length alone.
This reanalysis of data from 2 clinical trials evaluated the relative risk of fast axial eye growth in children wearing ortho-k lenses. The results showed that although younger children (6-8 years) experienced faster eye growth than older children (9-12 years), they also benefitted more from ortho-k in slowing their progression when worn for a 2-year period.
This prospective observational study found that DIMS spectacle lenses, atropine 0.01% and the combination of the two all showed robust efficacy for myopia control in European children. The combination treatment showed slightly better refractive control than the mono-therapies, but axial length growth was similar in all treatment groups.
Spectacle lenses for myopia control provide a clear central zone and a ‘treatment’ area for myopic defocus. This study found that atropine 0.01% and glare situations had minimal impacts on visual performance when adults wore the DIMS spectacle lens. This indicates likely tolerance of the combination in children.
This retrospective study from Ireland found that despite recent increases in practitioners fitting myopia control contact lenses in Ireland, more than 60% of children were still managed with single vision correction only. Improving the prescribing rates of evidence-based myopia control treatments will ensure progressing myopes are less likely to miss appropriate intervention opportunities.
